US20040266660A1 - Hdl for the treatment of stroke and other ischemic conditions - Google Patents

Hdl for the treatment of stroke and other ischemic conditions Download PDF

Info

Publication number
US20040266660A1
US20040266660A1 US10/487,224 US48722404A US2004266660A1 US 20040266660 A1 US20040266660 A1 US 20040266660A1 US 48722404 A US48722404 A US 48722404A US 2004266660 A1 US2004266660 A1 US 2004266660A1
Authority
US
United States
Prior art keywords
hdl
treatment
administered
ischemia
rhdl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/487,224
Other languages
English (en)
Inventor
Alphonse Hubsch
Markus Lang
Peter Lerch
Roberto Paterno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01120026A external-priority patent/EP1285662A1/en
Application filed by Individual filed Critical Individual
Priority to US10/487,224 priority Critical patent/US20040266660A1/en
Publication of US20040266660A1 publication Critical patent/US20040266660A1/en
Assigned to ZLB BIOPLASMA AG reassignment ZLB BIOPLASMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HUBSCH, ALPHONSE, LANG, MARKUS G., LERCH, PETER G., PATERNO, ROBERTO
Priority to US11/744,780 priority patent/US7491693B2/en
Assigned to WILMINGTON TRUST reassignment WILMINGTON TRUST SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LYDALL PERFORMANCE MATERIALS (US), INC., LYDALL, INC., SOUTHERN FELT COMPANY, INC.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Stroke can be classified into thrombo-embolic and hemorrhagic forms and is the third largest cause of death in western countries, after heart disease and cancer.
  • each year 600 000 people suffer a new or recurrent stroke (about 500 000 are the first attacks) and approximately 29% of them die within the first year (1).
  • the incidence of stroke increases with age, and in the elderly it is the leading cause of serious, long-term disability in the US accounting for total costs of 51.3 billion $/year (1).
  • the death rate from stroke has been decreasing in recent years, largely due to the increased awareness and better control of risk factors such as hypertension, hypercholesterolemia, arrhythmia or diabetes, the actual number of stroke deaths is rising because of an increasing elderly population.
  • prevention measures fail only limited and risky thrombolytic approaches exist, e.g. t-PA (tissue plasminogen activator). Neuronal protection could become a new and safer strategy for stroke treatment in the future (2-4).
  • Hemorrhagic shock comprises a generalized reduction in blood supply to the whole body which results in hypoxic damage that affects all organs and tissues.
  • ischemia describes a localized depletion of blood supply to specific organs and tissues, resulting in a rapid onset of anoxia in these affected regions. The mechanisms of damage are therefore quite distinct.
  • the pathophysiology of stroke is characterized by a wide range of homoeostatic, hemodynamic and metabolic abnormalities such as thrombus formation, impaired endothelial function and an activated inflammation cascade, i.e. increased cytokine production and expression of adhesion molecules (10-15).
  • Another hallmark of stroke is the augmented oxidative stress after reperfusion which is thought to play a detrimental role in the progression of the disease.
  • Prolonged ischemia results in an elevation of intracellular Ca ++ and the consequent activation of proteases and phospholipases results in formation of numerous potentially damaging products of membrane lipid breakdown. These include arachiodonic acid metabolites, which, in the presence of oxygen during reperfusion, provide a source of free radical formation (e.g. superoxide and hydroxyl anions). These free radicals induce blood brain barrier destruction and neuronal apoptosis and/or necrosis.
  • Apoptosis is a form of cell death that eliminates compromised or superfluous cells with no inflammatory response and is differentiated from necrosis by many morphological and biochemical characteristics. The feature of apoptosis can be found in both neurons and glia after ischemic injuries.
  • HDL can improve the outcome following excitotoxic and ischemic/reperfusion neuronal damage, particulary apoptosis and/or necrosis in the ischemic area and in the penumbra. Further, it was shown in an animal model for hemorrhagic shock that HDL reduces the PMN infiltration and prevents organ injury and dysfunction. At present, the mechanism of action is unknown. While not wishing to be bound by theory, it is possible that HDL might act as a free oxygen radical scavenger, vasodilator, e.g.
  • the invention generally relates to the use of HDL for the prophylaxis and/or treatment of ischemia or reperfusion injury.
  • Ischemia to an organ occurs as a result of interruption to its blood supply, and in its broadest sense may result in organ dysfunction or damage, especially heart, cerebral, renal, liver or lung. It is a local event/interruption that leads to complete or partial and in some cases reversible damage.
  • Reperfusion injury occurs as a consequence of rapid return of oxygenated blood to the area following ischemia and is often referred to in cardiovascular and cerebral misadventures.
  • a subject matter of the present invention is the use of HDL for the manufacture of an agent for the prophylaxis and/or treatment of ischemia or reperfusion injury.
  • HDL may be used for the prophylaxis and/or treatment of a disorder selected from ischemic stroke, ischemic tissue injury, e.g. ischemic injury of organs, cardiac ischemia, cardiac reperfusion injury and complications resulting from organ transplantation, e.g. kidney, heart and liver or cardio-pulmonary bypass surgery and other disorders.
  • ischemic tissue injury e.g. ischemic injury of organs, cardiac ischemia, cardiac reperfusion injury and complications resulting from organ transplantation, e.g. kidney, heart and liver or cardio-pulmonary bypass surgery and other disorders.
  • a further embodiment of the invention relates to the use of HDL for prophylaxis and/or treatment of transient ischemic attacks (TIA).
  • TIAs are common and about one third of those affected will develop a stroke some time later.
  • the most frequent cause of TIA is the embolization by a thrombus from an atherosclerotic plaque in a large vessel (typically a stenosed atheromatous carotid artery).
  • HDL has anti-atherosclerotic properties, as shown in studies looking at endothelial function through the restoration of bioavailability of nitric oxide, regulation of vascular tone and structure (9) it is thought that HDL may play a role in stabilizing an atheromatous plaque causing TIAs thereby reducing the risk of a major stroke.
  • Current therapy for TIAs include antiplatlet therapy, aspirin, ticlopidin and surgical intervention such as endoarterectomy. However, none of these provide, as yet, a substantial reduction in morbidity.
  • a further embodiment relates to the prophylactic administration of HDL to risk patient groups such as patients undergoing surgery.
  • Administration of HDL may reduce the incidence and/or severity of new strokes.
  • Prophylactic administration of HDL could also be useful in patients with TIAs, atrial fibrillation and asymptomatic carotid stenosis.
  • HDL high-density lipoprotein
  • stroke and transient ischemic attacks fulfills an as yet unmet clinical need. It provides a clinically effective neuroprotective therapy for individuals with traumatic brain injury.
  • HDL as used in the present invention relates to particles similar to high density lipoproteins and comprises nascent HDL or reconstituted HDL (rHDL) or any mixture thereof. Such particles can be produced from a protein or peptide component, and from lipids.
  • HDL also includes within its breadth any recombinant HDL or analogue thereof with functional relationship to nascent or reconstituted HDL.
  • the proteins are preferably apolipoproteins, e.g. human apolipoproteins or recombinant apolipoproteins, or peptides with similar properties.
  • Suitable lipids are phospholipids, preferably phosphatidyl choline, optionally mixed with other lipids (cholesterol, cholesterol esters, triglycerides, or other lipids).
  • the lipids may be synthetic lipids, naturally occurring lipids or combinations thereof.
  • HDL may result, on one hand, in a short term effect, i.e. an immediate beneficial effect on several clinical parameters is observed and this may occur not only within 3 hours of onset of stroke, but even 6 hours or possibly even longer and, on the other hand, a long term effect, a beneficial alteration on the lipid profile may be obtained. Furthermore, HDL resembles very closely substances naturally occuring in the body and thus the administration of HDL is free of side effects.
  • HDL is preferably administered by infusion, e.g. by arterial, intraperitoneal or preferably intravenous injection and/or infusion in a dosage which is sufficient to obtain the desired pharmacological effect.
  • HDL may be administered before the start of ischemia (if foreseeable, e.g. before an organ transplantation) and/or during ischemia, before and/or shortly after reperfusion, particularly within 24 h-48 h.
  • the HDL dosage ranges preferably from 10-200 mg, more preferably 40-80 mg HDL (weight based on apolipoprotein) per kg body weight per treatment.
  • the dosage of HDL which is administered may be about 20-100 mg HDL per kg body weight (weight based on apolipoprotein) given as a bolus injection and/or as an infusion for a clinically necessary period of time, e.g. for a period ranging from a few minutes to several hours, e.g. up to 24 hours. If necessary, the HDL administration may be repeated one or several times.
  • Reconstituted high density lipoprotein may be prepared from human apolipoprotein A-I (apoA-I), e.g. isolated from human plasma, and soybean-derived phosphatidylcholine (PC), mixed in molar ratios of approximately 1:150 apoA-1:PC.
  • apoA-I human apolipoprotein A-I
  • PC soybean-derived phosphatidylcholine
  • an HDL e.g. nascent HDL, rHDL, recombinant HDL or an HDL-like particle
  • an HDL which has a molar ratio of protein (e.g. apolipoprotein A-1) and phospholipid in the range of 1:50 to 1:250, particularly about 1:150.
  • rHDL may optionally contain additional lipids such as cholesterol, cholesterol esters, triglycerides and/or sphingolipids, preferably in a molar ratio of up to 1:20, e.g. 1:5 to 1:20 based on the apolipoprotein.
  • Preferred rHDL is described in EP-A-0663 407.
  • HDL may be combined with the administration of other pharmaceutical agents such as thrombolytic agents, anti-inflammatory agents, neuro- and/or cardioprotective agents.
  • the present invention relates to a method for prophylaxis and/or treatment of ischemia or reperfusion injury comprising administering a subject in need thereof an effective amount of HDL.
  • HDL is administered to a human patient.
  • a nylon thread (diameter 0.22 mm) which has a distal cylinder of silicon (2 mm long, diameter 0.38 mm) of thermofusible glue was inserted in the lumen of ECA and advanced into the internal carotid artery up the origin of MCA. To restore the MCA blood flow, the nylon thread was removed and cut thirty minutes later.
  • Histological analysis Twenty-four hours after the surgery euthanasia was performed. The brains were rapidly removed, frozen in isopentane at ⁇ 50° C. and stored at ⁇ 80° C. Cryostat cut coronal brain sections (20 ⁇ m) were stained with thionine and analyzed using an image analyzer. The lesioned areas were delimited by the paleness of histological staining in alterated tissue compared to the color of healthy tissue. Regions of interest were determined through the use of a stereotaxic atlas for the rat and an image analysis system was used to measure the lesioned area.
  • rats received an intravenous infusion of saline (n 5) (5 ⁇ l/min) over 4 h. After 2 h the MCA of rats was occluded for 30 minutes followed by reperfusion. After twenty-four hours, rats were sacrified for histological analysis of the brain.
  • rats received intravenous infusion of rHDL (n 5) (5 ⁇ l/min) at a dose of 120 mg/kg over 4 h. After 2 h the MCA of rats were occluded for 30 minutes followed by reperfusion. Twenty-four hours later the rats were sacrificed for histological analysis of the brain. The results are shown in Table 3.
  • rHDL reduced brain necrotic volume by 76% as compared to control rats.
  • rHDL was administered 3 h after injury in the MCAo (middle cerebral artery occlusion) model.
  • MCA middle cerebral artery occlusion
  • rats temporary occlusion of the middle cerebral artery (MCA) was attained by inserting a nylon thread through the carotid artery and blood flow was restored 30 minutes later. After 3 hours they received an intravenous infusion of either rHDL (120 mg/kg over 4 h, 6 ml/kg over 4 h) or saline (6 ml/kg over 4 h).
  • the rats were randomly assigned to the rHDL or the control group.
  • necrotic volume was reduced by 64% as compared to control rats.
  • Rats were grouped into three treatment arms. Group 1 received a prophylactic dose of rHDL 2 hours before receiving a transient MCA occlusion (2 hour) and continued receiving treatment during the occlusion. The artery was then reperfused.
  • Group 2 received a transient MCA occlusion followed by reperfusion. Treatment with HDL was given either 3 hours or 6 hours later.
  • Group 3 received a permanent MCA occlusion and received treatment 3 hours or 6 hours after occlusion.
  • rats were examined for neurological change using four standard motor neurological tests, namely forelimb flexion, torso twisting, lateral push and mobility. The scores were added for each of the tests and the results presented in FIG. 1.
  • rHDL is efficacious as a prophylactic treatment before occlusion and as a therapeutic treatment at two different points of time after occlusion. More particularly, a prophylactic and therapeutic treatment may be combined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
US10/487,224 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions Abandoned US20040266660A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/487,224 US20040266660A1 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
US11/744,780 US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US31360501P 2001-08-20 2001-08-20
EP01120026.8 2001-08-20
EP01120026A EP1285662A1 (en) 2001-08-20 2001-08-20 Reconstituted HDL for the treatment of stroke and ischemic conditions
US60/313605 2001-08-20
US10/487,224 US20040266660A1 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
PCT/EP2002/009294 WO2003018047A2 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/744,780 Continuation US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Publications (1)

Publication Number Publication Date
US20040266660A1 true US20040266660A1 (en) 2004-12-30

Family

ID=26076691

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/487,224 Abandoned US20040266660A1 (en) 2001-08-20 2002-08-20 Hdl for the treatment of stroke and other ischemic conditions
US11/744,780 Expired - Lifetime US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/744,780 Expired - Lifetime US7491693B2 (en) 2001-08-20 2007-05-04 HDL for the treatment of stroke and other ischemic conditions

Country Status (10)

Country Link
US (2) US20040266660A1 (enExample)
EP (1) EP1425031B8 (enExample)
JP (1) JP4284177B2 (enExample)
AT (1) ATE396736T1 (enExample)
AU (1) AU2002340825B2 (enExample)
CA (1) CA2457840C (enExample)
DE (1) DE60226881D1 (enExample)
ES (1) ES2304452T3 (enExample)
WO (1) WO2003018047A2 (enExample)
ZA (1) ZA200401360B (enExample)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
EP2289490A1 (en) 2005-03-24 2011-03-02 Cerenis Therapeutics Holding SA Charged lipoprotein complexes and their uses
WO2012109162A1 (en) 2011-02-07 2012-08-16 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
US11097020B2 (en) 2009-10-09 2021-08-24 Signablok, Inc. Methods and compositions for targeted delivery
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
JP5601750B2 (ja) * 2007-03-01 2014-10-08 シーエスエル、リミテッド 糖尿病患者の内皮機能異常の治療
AU2007200908B2 (en) * 2007-03-01 2012-08-16 Csl Limited Treatment of endothelial dysfunction in diabetic patients
CN102802618B (zh) 2009-06-25 2014-06-18 泰特拉有限公司 烟酸和米曲肼的治疗组合
EP2676659A1 (en) 2009-07-16 2013-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) HDL comprising a therapeutic agent and use in therapy
US20120189612A1 (en) * 2011-01-25 2012-07-26 The Cleveland Clinic Foundation Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy
CA2830664A1 (en) * 2011-03-25 2012-10-04 The Trustees Of Columbia University In The City Of New York Pegylated human hdl particle and process for production thereof
EP3137899A2 (en) 2014-05-02 2017-03-08 Cerenis Therapeutics Holding SA Hdl therapy markers
WO2021191266A1 (en) 2020-03-25 2021-09-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Aerosolization of hdl for the treatment of lung infections
US20230372532A1 (en) * 2020-10-05 2023-11-23 Northwestern University Targeted ph sensitive liposomes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780592A (en) * 1995-12-20 1998-07-14 Hoechst Aktiengesellschaft Compositions comprising lipoproteins and crotonamide derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004500332A (ja) * 1999-07-08 2004-01-08 テュラリク　インコーポレイテッド Ｈｄｌコレステロール値を上昇させる組成物および方法
GB9919713D0 (en) * 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
AUPQ429399A0 (en) 1999-11-26 1999-12-23 Heart Research Institute, The Oxidized apolipoproteins and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780592A (en) * 1995-12-20 1998-07-14 Hoechst Aktiengesellschaft Compositions comprising lipoproteins and crotonamide derivatives

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289490A1 (en) 2005-03-24 2011-03-02 Cerenis Therapeutics Holding SA Charged lipoprotein complexes and their uses
EP2327396A2 (en) 2005-03-24 2011-06-01 Cerenis Therapeutics Holding SA Charged lipoprotein complexes and their uses
US20070110751A1 (en) * 2005-10-25 2007-05-17 Maclellan Robb Compositions and methods for reducing infarct size
US12036294B2 (en) 2009-10-09 2024-07-16 Signablok, Inc. Spherical rHDLs for targeted imaging
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US11097020B2 (en) 2009-10-09 2021-08-24 Signablok, Inc. Methods and compositions for targeted delivery
WO2012109162A1 (en) 2011-02-07 2012-08-16 Cerenis Therapeutics Holding S.A. Lipoprotein complexes and manufacturing and uses thereof
EP2767546A1 (en) 2011-02-07 2014-08-20 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and uses therof
EP4400511A2 (en) 2011-02-07 2024-07-17 Abionyx Pharma SA Lipoprotein complexes and manufacturing and uses thereof
EP3466969A1 (en) 2011-02-07 2019-04-10 Cerenis Therapeutics Holding SA Lipoprotein complexes and manufacturing and use thereof
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2021209823A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194798A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2023237927A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using lipid binding protein -based complexes
WO2023237935A2 (en) 2022-06-10 2023-12-14 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein-based complexes
WO2024150064A1 (en) 2023-01-13 2024-07-18 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Also Published As

Publication number Publication date
CA2457840A1 (en) 2003-03-06
WO2003018047A3 (en) 2004-01-29
EP1425031A2 (en) 2004-06-09
ZA200401360B (en) 2005-08-31
US20080108550A1 (en) 2008-05-08
DE60226881D1 (de) 2008-07-10
JP2005501110A (ja) 2005-01-13
HK1064304A1 (en) 2005-01-28
CA2457840C (en) 2011-10-11
US7491693B2 (en) 2009-02-17
AU2002340825B2 (en) 2007-07-05
EP1425031B8 (en) 2008-09-03
ATE396736T1 (de) 2008-06-15
WO2003018047A2 (en) 2003-03-06
JP4284177B2 (ja) 2009-06-24
ES2304452T3 (es) 2008-10-16
EP1425031B1 (en) 2008-05-28

Similar Documents

Publication Publication Date Title
US7491693B2 (en) HDL for the treatment of stroke and other ischemic conditions
AU2002340825A1 (en) HDL for the treatment of stroke and other ischemic conditions
KR101668137B1 (ko) 계면 활성 단백질 ｂ (ｓｐ－ｂ) 및 계면 활성 단백질 ｃ (ｓｐ－ｃ)의 유사체를 함유하는 개량된 재구성 계면 활성제 조성물
JPH05506034A (ja) アクチン結合性化合物の療法的使用
CN1248169A (zh) 含有3－环丙基甲氧基－n－(3,5－二氯－4－吡啶基)－4－(二氟甲氧基)苯甲酰胺和肺表面活性剂的治疗ards或irds的组合物
JP2024166198A (ja) 可溶性細胞外マトリックス組成物および血管内送達のための方法
CN1203861C (zh) 含有人参皂甙Rb1的脑血管再生/再造促进剂和继发性神经组织变性抑制剂
JP2002529394A (ja) 肺サーファクタント組成物を含有する治療セット
EP0588477A2 (en) Medicinal composition comprising TCF-II
EP1057489B1 (en) Use of midkine family proteins in the treatment of ischemic diseases
HK1064304B (en) Hdl for the treatment of stroke and other ischemic conditions
NO321126B1 (no) Salt av et BPC (Body protection compound) "kroppsbeskyttelsesforbindelse"-peptid, omfattende 8 aminosyrerester, kompatibelt, lagringsstabilt, farmasoytisk preparat, diagnostisk lagringsstabilt preparat, anvendelser og fremgangsmater derav.
WO2003061680A9 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
EP1285662A1 (en) Reconstituted HDL for the treatment of stroke and ischemic conditions
TWI311485B (en) Reconstituted hdl for the treatment of stroke and ischemic conditions
WO1998040096A1 (en) Preventives and/or remedies for multiple organ failure
US8106009B2 (en) Pharmaceutical composition for preventing or treating ischemic diseases
WO1995007710A1 (en) Remedy for wound
RU2290194C1 (ru) Антитромботическое, антикоагулянтное, фибриндеполимеризационное, фибринолитическое средство
HK1026145B (en) A composition for the treatment of irds and ards
CA2635342A1 (en) Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome
JPH08157492A (ja) 抗動脈硬化ペプチド
AU2003201287A1 (en) Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
HK1125048A1 (en) Method for treating or preventing ischemia reperfusion injury or multi-organ failure
HK1125048B (en) Method for treating or preventing ischemia reperfusion injury or multi-organ failure

Legal Events

Date Code Title Description
AS Assignment

Owner name: ZLB BIOPLASMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HUBSCH, ALPHONSE;LANG, MARKUS G.;LERCH, PETER G.;AND OTHERS;REEL/FRAME:018667/0055

Effective date: 20040506

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE

AS Assignment

Owner name: WILMINGTON TRUST, DELAWARE

Free format text: SECURITY INTEREST;ASSIGNORS:LYDALL, INC.;SOUTHERN FELT COMPANY, INC.;LYDALL PERFORMANCE MATERIALS (US), INC.;REEL/FRAME:057826/0962

Effective date: 20211001